Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Treace Medical Concepts (TMCI) Share-based Compensation (2020 - 2025)

Treace Medical Concepts' Share-based Compensation history spans 6 years, with the latest figure at $7.6 million for Q4 2025.

  • For Q4 2025, Share-based Compensation fell 11.69% year-over-year to $7.6 million; the TTM value through Dec 2025 reached $33.8 million, up 10.52%, while the annual FY2025 figure was $33.8 million, 10.52% up from the prior year.
  • Share-based Compensation reached $7.6 million in Q4 2025 per TMCI's latest filing, down from $8.0 million in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $9.6 million in Q2 2025 to a low of $402000.0 in Q1 2021.
  • Average Share-based Compensation over 5 years is $4.7 million, with a median of $4.4 million recorded in 2023.
  • Peak YoY movement for Share-based Compensation: skyrocketed 571.2% in 2021, then fell 11.69% in 2025.
  • A 5-year view of Share-based Compensation shows it stood at $1.3 million in 2021, then soared by 91.03% to $2.5 million in 2022, then soared by 137.73% to $5.9 million in 2023, then soared by 45.69% to $8.6 million in 2024, then dropped by 11.69% to $7.6 million in 2025.
  • Per Business Quant, the three most recent readings for TMCI's Share-based Compensation are $7.6 million (Q4 2025), $8.0 million (Q3 2025), and $9.6 million (Q2 2025).